

## Axinn's Partner Chad A. Landmon Quoted by The Pink Sheet Discussing the Lovenox Lawsuit

August 2, 2010

### ATTORNEYS

Landmon, Chad

### PRACTICE AREAS

Intellectual Property

Sanofi-Aventis' suit against FDA seeking to overturn its approval of generic Lovenox is an example of what FDA will face once it approves follow-on biologics. Lovenox is not a biologic, however, it is a complex compound that raises some of the same issues as biosimilars. Chad Landmon, Partner at Axinn, told *The Pink Sheet*, "I think similar arguments will be litigated with respect to follow-on biologics. One of the initial disputes at FDA and in the courts [will be whether a biologic] molecule is so large we don't know what the innovator product is."

The article, titled "Lovenox Lawsuit May Be Omen For Biosimilar Battles," was filed August 2, 2010, by *The Pink Sheet*